Tài liệu, văn bản bạn tìm kiếm
CCND1 gene, Disease defining antigen, Neural transcription factor SOX11, Liver-directed therapy, Metastatic pancreatic ductal adenocarcinoma, Primary leptomeningeal melanoma, NRAS inhibitors, Cerebrospinal fluid analysis, Organ preserving, Hepatic metastasis, Monocarboxylate transporters, Taurine-upregulated gene 1, Circular chromosome conformation capture, Vascular disruptive agent, Tumor resistance, Several prognostic factors, Urothelial carcinomas, Prostate cancer treatment, Telomerase-immortalized, Normal urothelial cells, Composite score, Cell cycle regulation, MSH6 Mutation, Circadian clock genes, Casein kinases, Wnt related mutation, Proteins participating, Lymphatic invasion, 5-fluorourcil, Pharmacokinetic monitoring, Dose algorithms, Receptor expression profile, Detailed analysis, Delayed reaction, High fever, Ectopic hepatocellular carcinoma, Cancer testis antigen, Umbilical cord mensenchymal stem cells, Collapsin response mediator protein 4, Opposite effects, Stable cells, Hpatic stellate cells, Bupleurum falcatum, Hypoxic CRC cell lines, CRC entities harboring, Infrared imaging, Asymmetrical thermographic pattern, IAP antagonists, Synergistic treatments, Overcome resistance in colorectal cancer cells, Edmondson-steiner grade, Differentiated degrees, Prognostic importance, Hypervolemic hyponatremia, Cell lung, Vascular markers, Solitary fibrous tumor, Radiation recall, Radiation-recall gastritis, Extramammary Paget’s vulvar disease, Alternative therapeutic, Type I alpha dendritic cells, TCR repertoire, Threonine kinases, S6 Kinase, While chemotherapy, Potential drug, L1 cell adhesion molecule, Multicellular spheroids, Protein arginine methyltransferase 5, Symmetrical dimethylation, NuRD chromatin-remodeling complexes, ALK-positive, Anaplastic lymphoma receptor tyrosine kinase, Pohar-Perme estimator, HELLP syndrome, Symptoms described, Identified CK1α, Novel tumor suppressor, CK1α leads, Melanoma cells, Fibrillin-1, Following diagnosis, Testicular germ cell tumours, Therapeutic benefit, Conjunctival malignant melanoma, Phenanthridinone derivative PJ34, Disseminated disease, Noradrenaline transporter, Response monitoring, Tumour cell migration, Breast cancer-specific mortality, Imaging-genomics, Thrombocytosis thresholds, Prognostic impact, Prospective clinical trials, Splice variant, Accurate basis, Encodes subunit, Cellular velocities, GIRK1 overexpression, Predicted-deleterious variants, Immunosuppressive therapy, Pharmacological interaction, Peritoneal cancer, Treat peritoneal cancer, Prognostic estimations, Germline CDKN2A mutation, RPLP1-C19MC fusion gene, Ovarian tumor proteases, Methotrexate-associated lymphoproliferative disorder, Total lesion glycolysis, Determine frequency, ERG fusion heterogeneity, Extremely heterogeneous, Identify NF-kB related pathways, 92-gene assay, Ampullary adenocarcinoma, Pathological heterogeneity, 4T1 breast carcinoma, Bone marrow metastasis, Treatment-related symptoms, Multivalent oligossacharides, Psychosocial issues, Mesenchyme transition, Tumour dissemination, Mesenchymal phenotype, Intravenous iron, Poor physical performance, Iron administration, Oncologic treatment, Psychological morbidity, Uro-oncology nurses, Binding domains, Anti-angiogenic treatment, HIF-related, Diffuse intrinsic pontine gliomas, Highly aggressive, Cell cycle analysis, Hormone receptor positive breast cancer, Prostate cancer incidence, Cholesterol-lowering therapies, Anti-invasive activities, Invasive mammary carcinoma, Galectin-7, Differential network analysis, Microenvironment crosstalk, Response criteria, Evaluating disease progression, Perpendicular short axis, Interleukin-12, Pathological features, Auto-immune thyroid dysfunction, While hypothyroidism, Cisplatin-based treatment, Standard treatment regimen, Cetuximab-based bioradiotherapy, Desmoid-type fibromatosis, Wait-and-see, Solid pseudopapillary neoplasms of the pancreas, Idiopathic cytopenia of undetermined significance, FAC chemotherapy, AC chemotherapy, Adjuvant leukoprotective, Current cytotoxic, Autoimmune myopathy, Proximal muscle weakness, Muscle inflammation, Oral tongue squamous cell carcinoma, PD-1 antibody, Minimal change disease, Rectum cancers, Castration resistance, Prostate cancer ranks, Tumor embolism, Involves recurrent amplifications, T-lymphoma invasion, Metastasis-inducing protein 1, Disease subset, Pelvic pressure, Locally advanced solid tumours, Hypoxiainducible factor 1α, Trigeminal ganglioneuroma, Drug uptake, Aging effect, Tongue squamous cell cancer, Chemorefractory advanced gastric cancer, Forkhead box P3, Antitumor immunity, Insulin-like growth factor binding proteins, Absolute neutrophil counts, Centromeric probes, Cell replication, Iron depletion, Luminal-type breast cancer cell, Hormone-independent, Moloney murine leukemia virus, Desmoplastic malignant pleural mesothelioma, Rare histological subtype, Racial difference, Nodular melanoma, Superficial spreading melanoma, Acral lentiginous melanoma malignant, Lentiginous melanoma malignant, Hepatic vein tumor thrombosis, Veno-venous bypass, Human anion exchanger, Consumer quality index, Regulate intracellular pH, Healthcare evaluation, Particularly abundant, Parietal cells, Clinical T4, Alpha-glucanotransferase, Drives rapid proliferation, Mediated Motility Receptor, Cycle threshold, Non-tumourigenic cells, Cancer stem cell model, Originally attributed, Equally tumourigenic, MicroRNA-mediated resistance, HepG2 human hepatoma cell line, Sufficient oxygen, Mammary tumor, Translocated-externalized, Chaperone protein, Interstitial opacities, Oncologic treatments, Progressive dyspnea, Breast care unit, Synthetic antihepatitis drug, Anti-proliferation, Autophagy induction, ß-catenin, Distant metastatic tumor, Oxygen levels, Leukemic cells, Induce resistance, Anti-leukemic drugs, Fluorouracil implants, CDDP-induced nephropathy, Peritoneal chemotherapy, Thyroid malignancy, Consequential overtreatment, γ-glutamylcyclotransferase, Anti-proliferative, Target drugs, Case rep, Ethnic inequalities, MiR-211 genes, Cooking oil fume exposure, Multiplicative scales, Unexpected adverse, During pazopanib treatment, Breast tumour cells, Including mitochondria, Expression arrays, Sequential biopsy, Drug efficacy, Deleted in colorectal cancer, Serine proteases, Weakly expressed, Oncogenic behaviour, Prone breast radiotherapy, Dose homogeneity, Acute radiation dermatitis, MPACT trial, Subsequent therapy, Decision support techniques, Claudin-4, Transmembrane protein, Epithelial ovarian tumors, Therapeutic utility, CUB and Sushi multiple domains 1, Immunohistochemistry analysis, Hypoxia-inducible factor 2 alpha, Extramedullary erythropoiesis, VHL mutations, Karnosky performance score, Histon deacetylase inhibitors, G0/G1 cell cycle arrest, Intrinsic apoptotic pathway, TSA-mediated anti-lymphangiogenic, RAS testing, Laboratory practices, CRC-related deaths, Non-academic settings., Leucine supplementation, Pharyngeal cancer, Dysphagia-optimised intensity-modulated radiotherapy, Pharyngeal constrictor muscle, Supraglottic larynx, Splenic hilar lymph node dissection, Splenic preservation, Middle-third AGC, Tumor apelin, Serum apelin, Sympatho-adrena, Diverse cancers, Early death, Life expectancy criterion, Drug trials, Oncological rehabilitation, Tailored treatment methods, Specific intervention treatment, Extramedullary plasmacytoma, Adult population worldwide, Metronomic chemotherapy, Bevacizumab compared, Topoisomerase-I inhibitor, Gastro-oesophageal junction adenocarcinoma, Safety profile, Oesophago-gastric adenocarcinoma, Single-center retrospective, Novel therapeutic agents, Maxillary cancer, Non-epithelial, Pulmonary toxicity, Cost and cost analysis, Tumor-associated angiogenesis, Oral corticosteroids, Translational cancer research, Genetic variant, Functional assays, Multiple cell lines, Disseminated carcinomatosis of the bone marrow, Diffuse bone metastases, Associated-mortality, Clinically applicable biomarkers, Src/Erk signalling pathway, Tumour cell sensitivity, Dual inhibitor, Surgical re-resection, Interventional radiology treatment, Treatment-related side-effects, Hepatopancreatobiliary tumor, Cholangio carcinoma, Myo-inositol trispyrophosphate, Metastatic lymph node ratio, Lysophosphatidic acid receptor, Metastatic ovarian cancer cell lines, Stress-management intervention, Minimal-contact, ECM metagenes, Endothelial metagenes, Identify metagenes, Luteinizing hormone releasing hormone, Tyrosine residues, Brucea javanica oil, Radiotherapy and chemotherapy, Subcellular localisation, Treat ovarian cancer, Visceral organs, Myoepithelial carcinoma, Malignant myoepithelioma, Ex pleomorphic adenoma, Major salivary gland, HER-2 protein overexpression, Multiple primary cancers, Intestinal carcinogenesis, Regulating intra, Extracellular pH, Radiological imaging, Min mouse model, Cancer cell metabolism, Healthcare resource use, Inhibit cell survival, Wnt/β-catenin pathway, Women living with HIV, Cervical cytological abnormalities, Response Biomarker, Invasive intraductal papillary mucinous neoplasm, Non-invasive IPMN, Assessing response, Invasive IPMN, Adaptive biomarker, IPMN associated carcinoma, Pancreatic resection, Perioperative outcome, Cox multivariate analysis, NovoTTF-100A System, Tumor treating fields, Additional therapeutic, Fluorescent probes, Regulate somatic growth, Chemotherapy modified, Inhibition decreased chemoresistance, Cisplatin temozolomide, Parotid glands, Intravoxel incoherent motion, Secreted Frizzled-Related Protein 2, Osteosarcoma invasion, Dynamic contrast-enhanced, Metastasis-associated, Aldehyde dehydrogenase 1, Let-7 miRNAs, Extramedullary relapse, Acute T lymphoblastic leukemia, Boron neutron capture therapy